US FDA declares Shire's Firazyr effective, safe for HAE ahead of panel
This article was originally published in Scrip
Ahead of a 23 June US FDA advisory committee meeting, agency drug reviewers said Shire's Firazyr (icatibant) significantly provided symptom relief from skin and abdominal attacks associated with hereditary angioedema (HAE), a rare, potentially life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.